- |||||||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen
Thionamide Induced Pancreatitis and Agranulocytosis, a Rare Case of Concurrence (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_1810;
She was given a 10mg dose of dexamethasone and sent home with antibiotics...She was admitted and started on filgrastim 5mcg/kg daily for thionamide-induced agranulocytosis...This change was suspected to be from propranolol, steroids, iodine load from her CT, and prior methimazole use...doi: 10.1001/jama.2023.19052. PMID: 37847271.
- |||||||||| De Novo Metastatic Breast Cancer after Bilateral Mastectomy in a Transgender Man Harbouring a Germline BRCA2 mutation (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_1766;
A multigenerational family history of breast cancer prompted genetic testing, identifying a BRCA2 germline mutation.Past medical history included brain stem glioma (diagnosed aged 13 years) with multiple intracranial surgeries, ventriculoperitoneal shunt, mild acquired brain injury, anxiety, and post-traumatic stress disorder.Anticancer treatment has consisted of chemotherapy (Abraxane, Capecitabine), endocrine therapy (Letrozole), targeted therapy (Palbociclib, Olaparib), radiotherapy, and antiresorptive therapy (Denosumab)...Risk reducing bilateral salpingo-oophorectomy (plus hysterectomy) was performed in February 2021; histology identified an atrophic endometrium and no pathologic features.Gender affirming hormone therapy was commenced in October 2017 in the form of testosterone undecanoate 1000mg intramuscularly every 12 weeks...The impact of masculinising hormone therapy on the future risk of breast cancer remains unknown and further longitudinal data are required. Guidelines for pre- and post-operative breast screening after top surgery in high-risk transmasculine patients remain critically important.
- |||||||||| Prolia (denosumab) / Amgen
Comparative Effectiveness Of Antiresorptive Vs. Anabolic Therapy In Women With Type 2 Diabetes: Results From A Randomized Pilot Trial (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_1585;
Till November 2023, 72-week follow up was completed for 23, 18, 16, and 14 participants in ZOL, DMAB, TPTD, and control groups, respectively. At 72 weeks, LS aBMD increased by 2.24% (95% CI: -0.03, 4.52) with ZOL, 0.19% (95% CI: -2.71, 3.10) with DMAB, 7.28% (95% CI: 3.11, 11.45) with TPTD and declined by -0.53% (95% CI: -3.47, 2.41) in controls (p=0.008).
- |||||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Romosozumab Use in a Patient With Osteogenesis Imperfecta Type 3 (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_1582;
Data on patients with OI type 3 is scarce. Our patient continued to sustain fractures despite therapy with oral and intravenous bisphosphonates prompting us to use Romosozumab, off-label.
- |||||||||| Prolia (denosumab) / Amgen
Adult-Onset Hypophosphatasia Presenting as Low Alkaline Phosphatase Level Following Denosumab Use for Osteoporosis (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_1579;
There is a need for better screening and diagnostic criteria for adult HPP patients whose ALP levels may not be initially low before initiating antiresorptive drugs for osteoporosis. The risk of adverse effects from therapy will likely vary significantly based on the clinical severity/presentation of HPP as some adults with lower ALP ranges might be more susceptible to developing atypical femur fractures (1).
- |||||||||| Prolia (denosumab) / Amgen
Adjuvant denosumab therapy for adult-onset central giant cell granuloma (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_1578;
Denosumab exerts its therapeutic effect in giant cell lesions by inhibiting osteoclast maturation, thereby suppressing osteolysis and giant cell formation. Our case suggests it could be considered first line adjuvant treatment for patients with large CGCG lesions.
- |||||||||| Prolia (denosumab) / Amgen
PPI Breaks a Leg! An Unusual Case of Atypical Femur Fracture (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_1566;
Overall, PPIs are positively associated with elevated fracture risk in multiple studies. Increased gastrin production and hypochlorhydria are the two main mechanisms that affect bone remodeling, decreasing bone turnover, impairing calcium absorption, and altering homocysteine levels through impairment of folate and vitamin B12 absorption.This case supports a potential association between long-term PPI use and atypical femur fractures.
- |||||||||| Prolia (denosumab) / Amgen, Decadron (dexamethasone) / Merck (MSD), Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Hypercalcemia of Immobilization (HCOM) Responding to COVID treatment: A mere coincidence or more? (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_1558;
HCOM is managed by physical therapy, IV hydration, and IV bisphosphonates. Since hypercalcemia of immobilization is a sclerostin-mediated bone resorption process, a short course of steroids or the use of anti-sclerostin monoclonal antibody Romosozumab can be a reasonable treatment consideration however more research is needed for that.
- |||||||||| cinacalcet HCl / Generic mfg.
Management Strategies for Hypercalcemia in Breast Cancer with Bone Metastases: A Focus on Glucocorticoids and Cinacalcet (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_1553;
This case demonstrates the unusual occurrence of elevated 1,25-dihydroxyvitamin D in the setting of solid tumor, thereby suggesting the utility of glucocorticoids as a treatment option for HCM resistant to usual therapy. It also shows the effectiveness of cinacalcet in managing non-PTH-mediated HCM, which possibly works via increased renal clearance of calcium and could be used as an additional effective therapeutic option in these patients.
- |||||||||| Prolia (denosumab) / Amgen
PTH-independent Hypercalcemia Secondary to Severe Tophaceous Gout Bone Erosion (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_1549;
In this case hypercalcemia appeared due to severe gouty arthropathy that resolved after treatment with uricase. It is likely that inflammation and granulomatous changes at the tophus-bone interface stimulated osteoclast activity and calcitriol production resulting in hypercalcemia.
- |||||||||| Prolia (denosumab) / Amgen
Recurrent hyperparathyroidism due to parathyromatosis (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_1533;
Due to the scarcity of cases, there are no well-defined clinical guidelines for diagnosis and management. While a great tool, Sestamibi scans in his case have been negative or not completely inclusive of foci that were later found in surgical pathology.
- |||||||||| Prolia (denosumab) / Amgen
A "PTH-mediated" Hypercalcemia of Malignancy (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_1528;
During the previous hospitalization, her admission calcium was 17 mg/dL and was treated with IV fluids, calcitonin, and zoledronic acid...The patient was managed as per hypercalcemia of malignancy guidelines with IV fluids and denosumab... This is a rare case of endometrial cancer with liver metastasis and ectopic PTH secretion by primary tumor leading to recurrent hospitalizations related to hypercalcemia.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Thyroid Acropachy: A Clinical Response to Teprotumumab (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_774;
This observation implies that the pathophysiology of thyroid acropathy encompasses the interplay between TSH receptor and IGF-1 receptor signaling, akin to Grave ophthalmopathy, and suggests that the direct skeletal effect of TSH may be caused by the interaction with IGF-1 pathway, as shown in pre-clinical study (2).Reference:(1). Fatourechi V et al, J Clin Endocrinol Metab.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen, VRDN-001 / Viridian Therap
Inhibition of IGF-1 Receptor Signaling and Ocular Fibroblast Cell Growth by VRDN-001 vs Teprotumumab (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_765;
The current research extends these findings by showing that VRDN-001 also provides more complete inhibition of IGF-1-mediated ERK phosphorylation (MAPK signaling pathway activation) and fibroblast cell growth. While teprotumumab and VRDN-001 share a similar mechanism of action, their binding properties are distinct, which may explain the differences in ligand blocking, antagonism of signaling, and inhibition of functional activity.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Proptosis Improvement with Teprotumumab is independent of race, ethnicity, gender and age from Three Global Randomized, Double-masked, Placebo-controlled Trials of Patients with Acute Thyroid Eye Disease (TED) (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_750;
P2, P3
While teprotumumab and VRDN-001 share a similar mechanism of action, their binding properties are distinct, which may explain the differences in ligand blocking, antagonism of signaling, and inhibition of functional activity. Subgroup analysis of proptosis response by tobacco use, race, and age showed that teprotumumab treatment led to significantly higher proptosis response versus placebo in all groups.Public
- |||||||||| methimazole / Generic mfg.
A case of refractory methimazole-induced agranulocytosis treated with high-dose G-CSF (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_747;
On day 4 of admission, tbo-filgrastim 450 mcg daily injections were started for persistent neutropenia...This conservative approach reflects a paucity of evidence supporting G-CSF use. Further research must investigate underlying mechanisms and clarify indications for G-CSF use to improve outcomes and reduce costs of care.
- |||||||||| Prolia (denosumab) / Amgen
PTH-independent, Calcitriol-mediated hypercalcemia in Renal cell carcinoma (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_541;
Usually, the etiology for hypercalcemia in patients with renal cell carcinoma is the overproduction of PTHrP, which was not the case with our patient. The ultimate resolution of hypercalcemia of malignancy was attained by treating the underlying malignancy.
- |||||||||| Prolia (denosumab) / Amgen, Erleada (apalutamide) / J&J
A Case of Tumour-induced Osteomalacia Which Remitted After Treatment of Metastatic Prostate Cancer. (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_525;
SC denosumab 60mg Q6monthly was also commenced in view of extensive bone metastases...Despite metastatic disease, this patient responded exceedingly well to his cancer therapy. Suppression of the tumour cells with androgen deprivation therapy resulted in the lack of phosphotonin production and remission of his TIO.
- |||||||||| Journal, Metastases: Sequencing considerations in the third-line treatment of metastatic colorectal cancer. (Pubmed Central) - May 3, 2024
In the 2nd stage of the study, the Rego dose will be reduced to 60 mg/day to improve safety. Four treatments-regorafenib, trifluridine/tipiracil alone or with bevacizumab, and fruquintinib-are FDA-approved and recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
- |||||||||| zamaporvint (RXC004) / Redx
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Monotherapy: PORCUPINE: A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC) (clinicaltrials.gov) - May 3, 2024
P2, N=25, Completed,
Four treatments-regorafenib, trifluridine/tipiracil alone or with bevacizumab, and fruquintinib-are FDA-approved and recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines Recruiting --> Completed | N=50 --> 25 | Trial completion date: Dec 2023 --> Apr 2024 | Trial primary completion date: Aug 2023 --> Apr 2024
- |||||||||| Pharmacological interventions (Main Auditorium) - May 3, 2024 - Abstract #EAN2024EAN_700;
There was also no effect of a casein- derived angiotensinconverting enzyme inhibitory peptide (Met- Lys- Pro) on cognitive function. Still ongoing many trails that evaluate gene therapies targeting APOE4, APOE2, and NGF in addition to beta- amyloid and tau, anti- hypertensive treatment (IMPACTS- MIND and IPAT trial), semaglutid, SGLT2 inhibitors, DPP- 4 inhibitors, metformin, intranasal insulin, lecanemab, donanemab, atorvastatin and lithium carbonate.
- |||||||||| Opdivo (nivolumab) / BMS, Stivarga (regorafenib) / Bayer
Enrollment closed: INTEGRATEIIb: RegoNivo vs Standard of Care Chemotherapy in AGOC (clinicaltrials.gov) - May 3, 2024
P3, N=450, Active, not recruiting,
Still ongoing many trails that evaluate gene therapies targeting APOE4, APOE2, and NGF in addition to beta- amyloid and tau, anti- hypertensive treatment (IMPACTS- MIND and IPAT trial), semaglutid, SGLT2 inhibitors, DPP- 4 inhibitors, metformin, intranasal insulin, lecanemab, donanemab, atorvastatin and lithium carbonate. Recruiting --> Active, not recruiting
- |||||||||| Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Clinical, Journal: 3D-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate. (Pubmed Central) - May 2, 2024
3D-SHAPER analysis provides a novel technique for estimating changes in cortical and trabecular parameters from standard hip DXA images. These data add to the accumulating evidence that romosozumab improves hip bone density and structure, thereby contributing to the antifracture efficacy of the drug.
- |||||||||| Stivarga (regorafenib) / Bayer
Journal: Upregulation of LHPP by saRNA inhibited hepatocellular cancer cell proliferation and xenograft tumor growth. (Pubmed Central) - May 2, 2024
When combined with targeted anticancer drugs (e.g., regorafenib), LHPP saRNA exhibited synergistic effect in inhibiting in vitro HCC proliferation and in vivo antitumor growth in a xenograft HCC model. Findings from this study provides further evidence for a tumor suppressor role of LHPP and potential therapeutic value of restoring the expression of LHPP by saRNA for the treatment of HCC.
- |||||||||| Nexletol (bempedoic acid) / Esperion Therap, Otsuka, Daiichi Sankyo
Journal: A new indication for bempedoic acid (Nexletol). (Pubmed Central) - May 2, 2024
Findings from this study provides further evidence for a tumor suppressor role of LHPP and potential therapeutic value of restoring the expression of LHPP by saRNA for the treatment of HCC. No abstract available
- |||||||||| Sintbilo (tafolecimab) / Innovent Biologics
Review, Journal: Hypercholesterolemia: a literature review on management using tafolecimab: a novel member of PCSK9 monoclonal antibodies. (Pubmed Central) - May 2, 2024
Hyperlipidemia management includes various lipid-lowering drugs, including statins, Bempedoic acid, inclisiran, Lomitapide, ANGPTL3 inhibitors, and PCSK9 inhibitors...It has also been found that Tafolecimab has more affinity for PCSK9 and a longer duration of LDL-C reduction than other monoclonal antibody drugs such as evolocumab...Regulatory authorities like the FDA and EMA should also evaluate Tafolecimab's risks and benefits. In conclusion, Tafolecimab shows potential as an innovative therapeutic option for hypercholesterolaemia, particularly in patients with specific risk factors, but warrants additional research.
- |||||||||| Vectibix (panitumumab) / Amgen
Panitumumab's acneiform eruption treated with Bactrim: Case report () - May 2, 2024 - Abstract #INDERCOS2024INDERCOS_263;
The EGFR inhibitor- induced lesions are consistent with the described acneiform eruption in the literature: a folliculocentric, erythematous papule or pustule in areas rich in sebaceous glands such as the face, especially nose, cheeks, and nasolabial folds, and upper chest and neck. A skin biopsy is not routinely performed nor needed for the diagnosis.
- |||||||||| Enbrel (etanercept) / Pfizer, Amgen
Better IVIG Choice for Dermatologist in TEN () - May 2, 2024 - Abstract #INDERCOS2024INDERCOS_100;
A skin biopsy is not routinely performed nor needed for the diagnosis. Combination of IVIg (total dose of 2g/kg, for 5 days) with corticosteroids(1.5 mg/kg/day of methylprednisolone for 3 to 5 days) may synergistically create beneficial treatment effects by simultaneously targeting different pathways(1,3-8):
- |||||||||| Biologic and Small-Molecule Treatments in Scalp and Nail Psoriasis () - May 2, 2024 - Abstract #INDERCOS2024INDERCOS_40;
6 Roflumilast foam 0.3% was evaluated in a phase II trial in patients with scalp and body psoriasis...A total of 68 studies on 15 nail psoriasis targeted therapeutic agents which are TNF-alpha inhibitors (adalimumab, infliximab, etanercept, certolizumab, golimumab), IL-17 inhibitors (ixekizumab, brodalumab, secukinumab), IL-12/23 inhibitors (ustekinumab), IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab), PDE-4 inhibitors (apremilast), and JAK inhibitors (tofacitinib)...9 The therapy choices in NP have increased with the approval of new biologics and small molecules such as brodalumab, risankizumab, tildrakizumab, bimekizumab, and deucravacitinib...However, most RCTs assessing SP and NP outcomes are subgroup or post-hoc analyses of patients with scalp and nail involvement among larger PsO/PsA populations. RCTs particularly focusing on SP and NP are needed for better evaluation of efficacy and safety results of biologic and small molecule inhibitors.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen, Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date: Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 2, 2024
P1/2, N=36, Recruiting,
RCTs particularly focusing on SP and NP are needed for better evaluation of efficacy and safety results of biologic and small molecule inhibitors. Trial completion date: Apr 2024 --> Oct 2024 | Trial primary completion date: Apr 2024 --> Oct 2024
|
